1. In this randomized trial, amivantamab-lazertinib led to significantly longer progression-free survival than osimertinib therapy for mutated advanced non-small-cell lung cancer ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click to read the study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
1. The objective response rate was 29.8% (1% complete response, 66% partial response) with a PFS of 5.5 months and ...
1. The 5-year overall survival had a hazard ratio of 0.49, and this benefit was generally consistent across subgroups (stage, ...
